ClinicalTrials.gg
RecruitingNCT06275386IMAGINATIONUpdated Jan 2, 2026

Drug-Coated Balloon in Native Chronic Total Occlusion Percutaneous Coronary Intervention

An interventional study of Paclitaxel Drug-coated balloon in Coronary Artery Disease and Total Occlusion of Coronary Artery, sponsored by National Institute of Cardiology, Warsaw, Poland. Recruiting at 1 site in Poland. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-01-02.

Sponsored by National Institute of Cardiology, Warsaw, Poland · Not applicable, Interventional, and Treatment

How we know

From the registry’s dates

  • Primary completion was expected by Dec 2025, 10 months ago, but the record still lists the study as recruiting.
  • Started Mar 2024; still recruiting 2 years 7 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
30
Allocation
Not applicable
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 18 studies in Coronary Artery Disease by National Institute of Cardiology, Warsaw, Poland — 5 open to participants now, 5 under way, none of them phase 3. Coronary Artery Disease · National Institute of Cardiology, Warsaw, Poland.

Planned enrollment
12th of 12
30 · median 97
Started
2024
the only one that year
No phase
9 of 18
3 open now
Registered
15th of 18
by date

Among the 18 studies in Coronary Artery Disease by National Institute of Cardiology, Warsaw, Poland, this one is the 12th largest by planned enrollment of the 12 interventional ones that give a count, is the only one that started in 2024, is one of 9 with no phase, and was the 15th registered.

Coronary Artery Disease

4,866 studies on the registry are indexed under Coronary Artery Disease; 892 are open to participants now.

Browse Coronary Artery Disease studies →

Open to participants now

5 of the 18 studies in Coronary Artery Disease by National Institute of Cardiology, Warsaw, Poland are open now, in 1 country. Recruiting first, the newest first:

By country, each count listing its studies:

All 5 open studies →

Who these studies take

Of the 591 Coronary Artery Disease studies recruiting now, 404 (68%) set no upper age limit and 68 (12%) stop at 75 or younger; 37 take children under 18; 49 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 18 studies in Coronary Artery Disease by National Institute of Cardiology, Warsaw, Poland, or all of them as a file.
02

Study summary

The IMAGINATION trial is an investigator-initiated, prospective, single-center study of symptomatic patients with a native chronic total occlusion (CTO) undergoing intravascular ultrasound (IVUS)-guided percutaneous coronary intervention (PCI) with a drug-coated balloon (DCB). Post-PCI IVUS and fractional flow reserve (FFR) at baseline and at 6-months follow-up will be performed. In addition, patients included in the coronary computed tomography angiography (CCTA) substudy will undergo CCTA at 12-months follow-up. The aim of this study is to evaluate the efficacy and safety of DCB-only approach in native coronary CTO.

Read the detailed description

Whereas CTO PCI techniques and success rates have significantly improved during the last decade, CTOs still pose a significant technical challenge for accurate stent sizing (primarily due to negative remodelling and subsequent distal vessel dilatation post-PCI) resulting in a potentially increased risk of stent failure. Hence, the concept of DCB as a definitive treatment for native CTO is appealing and warrants further investigation. The IMAGINATION trial has been designed as a prospective research to: 1) investigate both the immediate and intermediate-term angiographic, IVUS and physiologic efficacy outcomes as well as safety profile of DCB for native vessel coronary CTO, and 2) to provide a basis for future randomized clinical trial comparing DCB to drug-eluting stents.

All patients with CTO will be screened for potential inclusion in the study. After obtaining written informed consent, patients with successful intraplaque guidewire crossing through CTO lesion (excluding the use of dissection and re-entry techniques) will undergo IVUS-guided PCI with a scoring balloon (balloon-to-artery ratio of 1:1) followed by the use of a paclitaxel-coated balloon. Following satisfactory angiographic result, IVUS and physiological measurements (FFR and non-hyperemic pressure ratios) in the target vessel will be performed. At 6-months follow-up, invasive angiography with IVUS and FFR/non-hyperemic pressure ratios in the target vessel will be repeated. In addition, patients with pre-procedural CCTA will undergo follow-up CCTA after 12 months (CCTA substudy).

03

Conditions studied

  • Coronary Artery Disease
  • Total Occlusion of Coronary Artery

Keywords

  • chronic total occlusion
  • percutaneous coronary intervention
  • drug-coated balloon
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • clinical indication for CTO PCI as determined by the local heart team (presence of angina or equivalent symptoms and/or documented ischemia or viability)
  • native CTO lesion as defined by invasive coronary angiography
  • for participation in the study

Exclusion criteria

Exclusion Criteria:

  • \<18 years of age
  • myocardial infarction
  • cardiogenic shock
  • severe valvular disease
  • estimated \<1 year
  • to PCI
  • positive pregnancy test or breast-feeding
  • in-stent CTO
  • CTO recanalization using antegrade or retrograde dissection and re-entry techniques
Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
30 participants (estimated)

Study arms

  • Experimental
    Drug-coated balloon

    Patients will undergo PCI of the native coronary CTO with a DCB.

    Device: Paclitaxel Drug-coated balloon

Interventions

  • DevicePaclitaxel Drug-coated balloon

    Percutaneous coronary intervention of the actual CTO body with a paclitaxel drug-coated balloon.

06

What researchers measure

Primary outcomes

  1. In-segment late lumen loss

    The difference by subtracting the minimal lumen diameter (MLD) at follow-up from the MLD postprocedure. In-segment equals DCB plus the proximal and distal 5-mm margins.

    Time frame: 6-months

Secondary outcomes

  1. Angiographic outcomes assessed directly post-PCI

    * minimum lumen diameter (mm) * residual diameter stenosis (%) * the rate of bail-out stenting after DCB use (%)

    Time frame: immediately post-procedure (1 day)

  2. HD-IVUS outcomes assessed directly post-PCI

    * minimal lumen diameter (mm) * minimal lumen area (mm2) * maximum plaque burden (%)

    Time frame: immediately post-procedure (1 day)

  3. Physiologic outcomes assessed directly post-PCI

    * the ratio of pd/pa * cRR (absolute values) * FFR (absolute values)

    Time frame: immediately post-procedure (1 day)

  4. Angiographic outcomes at 6-months follow-up

    * minimum lumen diameter (mm) * residual diameter stenosis (%) * in-segment binary restenosis (≥50% diameter stenosis) * the rate of target vessel re-occlusion (yes/no)

    Time frame: 6-months

  5. HD-IVUS outcomes at 6-months follow-up

    * minimal lumen diameter (mm) * minimal lumen area (mm2) * maximum plaque burden (%)

    Time frame: 6-months

  6. Physiologic outcomes at 6-months follow-up

    * the ratio of pd/pa * cRR (absolute values) * FFR (absolute values)

    Time frame: 6-months

  7. Computed tomographic outcomes at 12-months follow-up (CCTA substudy)

    * minimal lumen area (mm2) * maximum plaque burden (%) * area stenosis (%) * diameter stenosis (%) * remodeling index (absolute values) * total plaque volume (mm3) * calcified plaque volume (mm3) * non-calcified plaque volume (mm3) * low-attenuation plaque volume (mm3) * percentage of change in in-segment total plaque volume (%) * percentage of change in in-segment calcified plaque volume (%) * percentage of change in in-segment non-calcified plaque volume (%) * percentage of change in in-segment low-attenuation plaque volume (%) * percentage of change in in-segment remodeling index (%)

    Time frame: 12-months

  8. Clinical outcomes at 12-months follow-up

    • the rate of target lesion failure (composite endpoint of cardiac death, target vessel-related myocardial infarction, or clinically-driven target lesion revascularization)

    Time frame: 12-months

07

Study locations

1 of 1 sites recruiting
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Mar 2024 (actual). Primary completion is estimated for Dec 2025, 21 months after the start.

Of 756 non-industry interventional studies with no phase under Coronary Artery Disease, half reached primary completion within 33 months of starting (the median), counting those still running; a quarter within 15 and three quarters within 53. This study's planned 21 months is below that.

Counting every sponsor, half of 933 studies reached it within 30 months; a quarter within 15 and three quarters within 50.

How these figures are worked out, and which studies are left out of them.

Registered
Feb 7, 2024
First posted
Feb 23, 2024
StartActual
Mar 24, 2024
Primary completionEst.
Dec 31, 2025
CompletionEst.
May 2026
Last update
Jan 2, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jan 2, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT06275386
Lead sponsor
National Institute of Cardiology, Warsaw, Poland
Responsible party
Sponsor
First posted
Feb 23, 2024
Start date
Mar 24, 2024
Primary completion
Dec 31, 2025 (estimated)
Completion
May 2026 (estimated)
Last update
Jan 2, 2026

Study contacts

Maksymilian Opolski
Contact
mopolski@ikard.pl
0048(22)3434127
Maksymilian Opolski
principal investigator · National Institute of Cardiology

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion